Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in several key investor conferences in March 2025.

The company will engage in fireside chats at the following events:

• TD Cowen 45th Annual Healthcare Conference in Boston (March 5, 9:10 a.m. ET)
• Leerink Partners Global Biopharma Conference in Miami (March 11, 8:00 a.m. ET)
• Jefferies Biotech on the Bay Summit in Miami (March 12, one-on-one meetings)
• H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (March 27, 10:30 a.m. ET)

Live webcasts will be accessible through the Investors section of Kymera's website, with replays available after the events.

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:

• TD Cowen 45^th Annual Healthcare Conference in Boston, MA on March 5 at 9:10 a.m. ET;
• Leerink Partners Global Biopharma Conference in Miami, FL on March 11 at 8:00 a.m. ET;
• Jefferies Biotech on the Bay Summit in Miami, FL on March 12, one-on-one meetings only; and
• H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27 at 10:30 a.m. ET.

Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.

About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Investor and Media Contact:  Justine Koenigsberg Vice President, Investor Relations investors@kymeratx.com media@kymeratx.com 857-285-5300

FAQ

What investor conferences will Kymera Therapeutics (KYMR) attend in March 2025?

Kymera will participate in four conferences: TD Cowen Healthcare Conference (March 5), Leerink Partners Global Biopharma Conference (March 11), Jefferies Biotech Summit (March 12), and H.C. Wainwright Autoimmune Conference (March 27).

How can investors access Kymera Therapeutics' (KYMR) March 2025 conference presentations?

Live webcasts will be available in the 'News and Events' section of Kymera's website (www.kymeratx.com), with replay access after the events.

What is the schedule for Kymera's (KYMR) presentation at the TD Cowen Healthcare Conference?

Kymera will present at the TD Cowen 45th Annual Healthcare Conference in Boston on March 5, 2025, at 9:10 a.m. ET.

Which of Kymera's (KYMR) March 2025 investor events will be virtual?

The H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Conference on March 27 will be virtual.